Frazier Life Sciences Management, L.P. Gracell Biotechnologies Inc. Transaction History

Frazier Life Sciences Management, L.P.

  • $1.86 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$2.08 - $5.15 $460,613 - $1.14 Million
-221,449 Reduced 7.12%
2,890,102 $9.31 Million
Q2 2022

Aug 10, 2022
SELL
$1.95 - $5.5 $652,122 - $1.84 Million
-334,422 Reduced 9.7%
3,111,551 $17.1 Million
Q1 2022

May 16, 2022
BUY
$1.83 - $5.52 $6.31 Million - $19 Million
3,445,973 New
3,445,973 $8.03 Million

Others Institutions Holding GRCL

# of Institutions
2
Shares Held
75.1K
Call Options Held
0
Put Options Held
0
View Full List

About Gracell Biotechnologies Inc.

GRCL Quotes by TradingView
  • Ticker GRCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,674,096
  • Description
  • Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...
More about GRCL
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email